Romosozumab Among Latest Drugs Up For CHMP Opinion
Executive Summary
Four drugs are up for an opinion this week on whether they should be granted EU-wide approval, including Amgen/UCB's osteoporosis drug romosozumab.
You may also be interested in...
GW Pharma's Cannabinoid Medicine Epidyolex Among CHMP Hopefuls
Seven new medicines, including GW Pharma's orphan cannabidiol product, Epidyolex, are due for an opinion from the European Medicines Agency this week on whether they should be recommended for pan-EU approval.
UK Pilot To Generate Real World Data On Medicinal Cannabis Use
Drug Science, a UK charity, is about to launch a 20,000-patient pilot project looking at the use of medicinal cannabis for conditions like chronic pain, multiple sclerosis and Tourette’s syndrome. It says a special licensing status for such products could eventually be possible.
UK Committee Attacks Pharma Over Lack Of Medicinal Cannabis Research
The pharmaceutical industry has come under attack by a UK parliament committee for failing to make medicinal cannabis products available for clinical trials, saying that a "robust research base" is needed on which to base future treatment decisions.